CRDL – cardiol therapeutics inc. - class a common shares (US:NASDAQ)
Stock Stats
News
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024 [Yahoo! Finance]
Cardiol Therapeutics Inc. (NASDAQ: CRDL) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.
Cardiol Therapeutics Announces Year-End 2023 Update on Operations [Yahoo! Finance]
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis [Yahoo! Finance]
Form 6-K Cardiol Therapeutics For: Mar 31
Form 6-K Cardiol Therapeutics For: May 14
Form 6-K Cardiol Therapeutics For: Apr 18
Form 6-K Cardiol Therapeutics For: Apr 02
Form 20-F Cardiol Therapeutics For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.